CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk

Abroad (travel likely)RecruitingPHASE2

Conditions

Metastatic Clear Cell Renal Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China

    Contact: Study coordinator (Le Qu, Ph.D.) · septsoul@hotmail.com · +86 15720625951
Study leads
  • Le Qu, Ph.D.

    Principal Investigator

    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University